Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Jun 6, 2016Virtual Press Office and PR Newswire: General Trade show news
S2C Inc., a worldwide leader of FPGA-based prototyping solutions for today's innovative designs, announced today that its Prodigy™ Player Pro 6.3 Runtime and Compile Software allows for more...
-
Jun 6, 2016InfoComm Tradeshow and Exhibitor News
The following event roundup from Virtual Press Office is a list of featured exhibitors for InfoComm 2016, the largest professional AV trade show in North America, which takes place from June 8-10...
-
Jun 5, 2016Summer Fancy Food Show News
To view full release, go to: https://www.specialtyfood.com/news/article/rishi-tea-organic-moonlight-jasmine-2016-sofitm-finalist-123583/
-
Jun 5, 2016Virtual Press Office and PR Newswire: General Trade show news
BERG, a biopharmaceutical company uncovering health solutions through a data-driven, biological research approach, today announced that it will present two poster presentations on the Phase 1...
-
Jun 5, 2016Virtual Press Office and PR Newswire: General Trade show news
Eli Lilly and Company (NYSE: LLY) today announced that clinical study data from two of its ongoing immuno-oncology clinical collaborations with Merck (known as MSD outside the U.S. and Canada)...
-
Jun 5, 2016Virtual Press Office and PR Newswire: General Trade show news
Genomic Health, Inc. (Nasdaq: GHDX) today announced results from seven Oncotype DX® studies being presented at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting. Results...
-
Jun 5, 2016Virtual Press Office and PR Newswire: General Trade show news
Data from the Phase 3 MMY3004 (CASTOR) clinical trial show the immunotherapy daratumumab (DARZALEX®) in combination with a standard of care therapy, bortezomib (a proteasome inhibitor [PI]) and...
-
Jun 5, 2016Virtual Press Office and PR Newswire: General Trade show news
AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that treatment with rovalpituzumab tesirine (Rova-T), a delta-like protein 3 (DLL3)-targeted antibody-drug conjugate (ADC),...
-
Jun 4, 2016Virtual Press Office and PR Newswire: General Trade show news
OBI Pharma, Inc., a Taiwan biotech company (TPex: 4174), today announced that Phase II/III data evaluating the clinical benefit and immunogenicity of OBI-822/OBI-821 (formerly OPT‐822/OPT-821),...
-
Jun 4, 2016Virtual Press Office and PR Newswire: General Trade show news
Two new studies co-authored by researchers from John Theurer Cancer Center (JTCC) at Hackensack University Medical Center and discussed at the American Society of Clinical Oncology (ASCO) annual...